Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/amorphous-solid-dispersions-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Pharmaceutical ManufacturingAmorphous Solid Dispersion Patents: Who Files, What They Claim, and Where Gaps Remain
- 22.6% concentration at the top. The five leading assignees hold 947 of 4,186 records in scope, but that still leaves the large majority spread across a long tail of single- and few-filing entrants.
- Filing has cooled from its 2021 peak. Filings ran from 387 in 2021 to 206 in 2024, a -47% move over that three-year span, the last window not distorted by publication lag.
- One IPC subclass dominates claim scope. A61K medicinal preparations appear in 90.2% of the 4,186 records, while therapeutic-activity and heterocyclic-compound classes trail well behind at 36.6% and 25.8%.
4,186
Published Records
23%
Top-5 Share of All Records
-47%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (387 records) with 2024 (206) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 4,186 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Field Overview
What the amorphous solid dispersion patent record shows
Amorphous solid dispersion technology addresses a specific formulation problem: poorly soluble drug compounds need a stabilized, non-crystalline state to achieve adequate dissolution and bioavailability. The patent record captured here, 4,186 records published between 2015 and mid-2026, centres on polymer carrier selection, hot melt extrusion processing, and the control of recrystallization risk and moisture sensitivity that governs shelf-life. Glass transition temperature control and dissolution enhancement claims recur across the corpus as the two technical levers assignees most often protect.
Filing activity peaked in 2021 and has since declined through the last complete filing year, 2024. Because publication typically lags filing by around 18 months, the most recent one to two years in any trend chart are still filling in and should not be read as a definitive slowdown.
Filing activity by year, 2017–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Amorphous Solid Dispersions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Numbers
Filing trends and technology composition
Two views of the same 4,186-record corpus: how filing volume has moved year over year, and how claim scope splits across IPC subclasses.
Filings rose to a 2021 peak, then eased
Annual filings moved from 233 in 2017 to a peak of 387 in 2021, then fell to 206 by 2024, a -47% change over that three-year span. 2025 and 2026 figures are still incomplete due to publication lag and should not be read as a continuation of the decline.
A61K dominates, C07D chemistry a secondary layer
A61K medicinal-preparation claims appear in 90.2% of the 4,186 records, far ahead of A61P therapeutic-activity claims at 36.6% and C07D heterocyclic-compound claims at 25.8%. Because records can carry multiple IPC codes, these shares sum to more than 100% and should be read as claim-scope overlap, not as a partition of the field.
Shares are the percentage of the 4,186 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Amorphous Solid Dispersions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Amorphous Solid Dispersions with Eureka
This page is one run against one query. Ask Eureka your own question about amorphous solid dispersions and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
The most-cited records and a representative filing
Representative Filing
Hot melt extrusion composition using direct compressible excipient as plasticizer
MERCK PATENT GMBH
The present invention relates to the use of spray-dried sorbitol, such as Parteck SI, as plasticizer for polymer containing compositions processed by hot melt extrusion. Due to its improved properties, achieved by its special manufacturing process, this direct compressible excipient shows more additional benefits than the same substance in crystalline state.Filed by Merck Patent GmbH, published 2020-08-13 as US20200254098A1.
Most-cited records in the corpus
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2007079139A2 | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | 267 |
| 2 | US20040013734A1 | Pharmaceutical solid dispersions | 264 |
| 3 | US20120140790A1 | Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Termperature or High Molecular Wei… | 239 |
| 4 | US20110294717A1 | Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weig… | 224 |
| 5 | WO2011119984A1 | Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-YL)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-… | 207 |
| 6 | US20110064811A1 | Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | 176 |
| 7 | WO2011084513A2 | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weig… | 172 |
| 8 | WO2011133951A1 | Pharmaceutical compositions and administrations thereof | 168 |
| 9 | WO2014014841A1 | Pharmaceutical compositions of ( r) -1-(2,2-diflurorbenzo[d][1,3]dioxol-5-YL)-n-(1-(2,3-dihydroxypropyl)-6-fl… | 158 |
| 10 | WO2015160787A1 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated… | 149 |
Citation counts favour older records simply because they have had longer to accumulate citations inside the searched corpus; treat them as a signal of influence rather than of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Amorphous Solid Dispersions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the data means for filing strategy
Three patterns worth acting on before drafting the next application in this space.
Concentration
22.6% / 947 records
top 5 share of all 4,186 records
The top tier is real but not dominant
The five leading assignees together hold 22.6% of all records in scope, and the top ten reach 32.1%. That leaves more than two-thirds of the corpus held by the ranked field beyond the leaders, so a freedom-to-operate review cannot stop at the household names.
Top 10 combined = 1,344 records, 32.1% of 4,186.
Momentum
-47%
2021 to 2024 filing change
Peak filing has passed, for now
Filings fell from 387 in 2021 to 206 in 2024. Some of the most recent filers named in the momentum data show renewed activity even as others have gone quiet, so the field is not uniformly retreating; it is reshuffling among assignees.
2025-2026 counts are still incomplete due to publication lag.
Claim scope
90.2%
records carrying A61K
Formulation claims crowd one subclass
Nearly all records touch A61K medicinal preparations, which means differentiation increasingly happens inside that subclass rather than by claiming a wholly separate IPC territory. Secondary classes like C07D heterocyclic chemistry (25.8%) mark where compound-specific claims layer on top.
IPC shares sum above 100% because records carry multiple codes.
Jurisdictions
786
US-filed records
US and EPO remain the primary filing offices
The United States leads receiving offices with 786 records, followed by the EPO at 547 and WIPO/PCT filings at 445. Australia, Israel and India each carry meaningful but smaller shares, indicating this is still primarily a US/Europe prosecution story with selective extension elsewhere.
Receiving office counts: US 786, EPO 547, WIPO 445, Australia 295, IL 292, India 274.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to amorphous solid dispersions, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Amorphous Solid Dispersions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Who's Filing
Leaders, collaborators and where the gaps sit
The ranked field spans 100 companies counted by patent family. A handful of large pharmaceutical and academic filers sit at the top, but co-filing patterns and recent momentum suggest the competitive picture keeps shifting.
Leader
422 records
leading assignee's family count
One filer sits well ahead of the field
The top-ranked assignee holds 422 records, more than four times the fifth-place total of 97. That gap indicates a sustained, deliberate filing programme rather than opportunistic protection around a single molecule.
Fifth place: 97 records; tenth place: 67 records.
Collaboration
10 pairs
co-assignee pairs identified
Co-filing clusters around a few repeat pairings
The strongest co-assignee pairing appears 31 times, well ahead of the next pairings at 28 and 25. These recurring pairs point to established research partnerships, often between an academic institution and a formulation specialist, rather than one-off joint filings.
Strongest pairing: 31 shared records; next two: 28 and 25.
Momentum
+100% YoY
one assignee's latest-year change
Recent activity is uneven across the top tier
Some previously active filers show zero filings in the latest year, while at least one assignee grew filings year over year. This split is typical of a maturing field: a few players are still investing in new formulation IP while others consolidate around earlier grants.
Latest-year filings range from 0 to modest increases among tracked assignees.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Les Laboratoires Servier | 4 | +100% |
| Board of Regents, The University of Texas System | 1 | 0% |
| Vertex Pharmaceuticals Inc | 0 | -100% |
| Agios Pharmaceuticals, Inc. | 0 | — |
| Gilead Pharmasset LLC | 0 | — |
| Pfizer Prod Inc | 0 | — |
| Novartis AG | 0 | -100% |
| Merck Patent GmbH | 0 | -100% |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Amorphous Solid Dispersions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Next Steps
Where to take this analysis
The dataset points to specific follow-up work depending on whether the goal is freedom-to-operate, portfolio strategy or new formulation R&D.
Map claim overlap inside A61K
With 90.2% of records touching one IPC subclass, the real differentiation lies in sub-claim language around carrier polymers and processing parameters. A claim-chart comparison inside that subclass will show where language is actually free.
Explore claim mapping in EurekaTrack the leading assignee's filing cadence
A single assignee holding 422 records against a fifth-place total of 97 warrants a standing watch on its continuation and divisional activity before committing to adjacent formulation work.
Set up assignee monitoring in EurekaTest white space in under-claimed branches
Sub-areas like sugar carrier systems and in-line process monitoring show thinner claim density than the core formulation classes. A first-claim draft there is worth stress-testing against the existing corpus before further R&D spend.
Run a white space search in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Amorphous Solid Dispersions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about amorphous solid dispersion patents
This dataset covers 4,186 published records from 2015 through mid-2026 that match amorphous solid dispersion and amorphous drug stabilization search terms combined with polymer carrier, hot melt extrusion, and related processing terms. The true worldwide total is likely somewhat different depending on search scope, but this corpus is large enough to show clear concentration and trend patterns. Because publication lags filing by roughly 18 months, the most recent one to two years will always undercount actual filing activity.
The ranking covers 100 companies by patent family count, with the leading assignee holding 422 records compared to 97 at fifth place and 67 at tenth. That gap between first place and the rest suggests one filer runs a much larger, sustained formulation programme than its peers. Beyond the top ten, filing activity spreads across a long tail of companies and academic institutions with far smaller portfolios.
No. Filings peaked at 387 in 2021 and had fallen to 206 by 2024, a -47% change over that span, which is the most recent period reliable enough to compare given publication lag. Figures for 2025 and 2026 are still incomplete and should not be read as evidence of continued decline. Some individual assignees show renewed year-over-year growth even as the aggregate trend has eased from its peak.
A61K, medicinal preparations, appears in 90.2% of the 4,186 records, making it by far the most common IPC classification in this space. A61P, therapeutic activity, and C07D, heterocyclic compounds, follow at 36.6% and 25.8% respectively, typically layered onto A61K claims rather than standing alone. Smaller classes covering biocides, sugar carriers, and mixing processes each account for under 2% of records, marking areas with comparatively less claim density.
The technology composition data shows several IPC subclasses with much lower record counts than the dominant A61K/A61P/C07D cluster, including sugar and nucleic acid carrier systems, agrochemical applications, and mixing or stirring process claims. These thinner areas do not guarantee an easy filing, but they indicate less crowded claim space relative to the core formulation classes. A proper freedom-to-operate search of the specific sub-claim language is still necessary before relying on this as a filing strategy.
Answers are grounded in the same dataset. Derived from a Patsnap search on Amorphous Solid Dispersions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Amorphous Solid Dispersions in depth with Eureka
Go past this page: query the whole amorphous solid dispersions corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.